Distribution of prescription drug exposures in the elderly: Description and implications

https://doi.org/10.1016/0895-4356(96)00055-8Get rights and content

Abstract

Using data from a comprehensive prescription drug benefit program in British Columbia, we studied the distribution of prescription drug expenditures and exposures in the community-dwelling elderly over a 1-year period. Overall, 84% of the population was exposed to at least one prescription drug. The 11% of individuals with the highest level of use accounted for 50% of total drug expenditures. Individuals 65 to 74 years of age were exposed to a median of 2.2 different drugs during the year compared to a median of 3.8 for those 75 years of age and over. Twenty-four percent of the 65- to 74-year-old population were exposed to six or more different drugs during a 1-year period compared to 37% of the 75 years and over population. Central nervous system and cardiovascular drugs were most commonly responsible for multiple drug exposures. Forty-eight percent of the individuals exposed to six or more different drugs received prescriptions from three or more different physicians. In British Columbia, 98% of the elderly receiving six or more different drugs received at least one prescription from a general practitioner or a family practitioner.

References (19)

There are more references available in the full text version of this article.

Cited by (48)

  • Safety and Clinical Outcomes of Abiraterone Acetate after Docetaxel in Octogenarians with Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme

    2016, Clinical Genitourinary Cancer
    Citation Excerpt :

    It is also a substrate of CYP3A4, increasing the risk of drug–drug interactions in patients taking it at the same time as strong CYP3A4 inhibitors (eg, fluconazole or erythromycin) or inducers such as carbamazepine, phenytoin, or rifampicin. Because patients aged > 75 years are generally exposed to a median of 3.8 different drugs (compared with 2.2 in those aged 65-74 years) and because 37% take as many as ≥ 6 (compared with 22% of those aged 65-74 years), the risk of adverse events from drug–drug interactions can be particularly significant in very elderly patients.20 In our patients, the incidence of comorbidities was mostly not different from that of the younger counterparts, highlighting patient selection by the comorbidity burden more than by a simple age-based criterion.

  • Systematic review of factors affecting pharmaceutical expenditures

    2014, Health Policy
    Citation Excerpt :

    There was methodological variation in the studies’ exploration of the factors affecting pharmaceutical expenditures. The methods include: analysis of prescription claims [13] and the structural effect approach [14]; decomposition of pharmaceutical spending growth [15]; dynamics of expenditure through time [16]; decomposition of change in real drug spending using a multiplicative growth equation [17]; decomposition of real drug spending into price, quantity and residual [18,19]; prescription drug expenditures [20–22]; decomposing the growth of pharmaceutical expenditures into three components: treatment expansion; treatment substitution; and price effect [23]; a pharmacoepidemiological model based on incidence, treatment discontinuation and drug user mortality [24];decomposition of the increase in real drug expenditures into a price effect, a volume effect, and a product-mix effect [25]; multiplicative factor equations using index numbers [26–29]; and equations describing changes in age/sex-specific expenditures [30]. Other studies included trend analysis [31–36] and fixed effects using regression analysis and the demographic impact method [37].

  • Psychiatry in the elderly: Issues and prospects

    2014, Annales Medico-Psychologiques
  • Acquisition cost of dispensed drugs in individuals with multiple medications-A register-based study in Sweden

    2011, Health Policy
    Citation Excerpt :

    To a large extent, the two groups include the same individuals [35] and the costs of drug therapy have been used to screen patients for a community pharmacy-based medication review program [36]. Although previous studies have mainly focused on patients with the highest drug cost and not on individuals with multiple medications, our findings that the overall drug costs are concentrated on a relatively small proportion of the population are in agreement with previous findings [33–35,37,38]. Furthermore, the observed female–male ratio (60:40) is in line with a previous report [35].

View all citing articles on Scopus

This study was funded under a grant from Health and Welfare Canada (NHRDP6610-1774-57). Dr. Anderson also received personal support from Health and Welfare Canada (NHRDP-6610-1737-48).

View full text